Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia-Pacific trial

详细信息    查看全文

• 作者：Ann-Lii Cheng^a ; ^{alcheng@ntu.edu.tw} ; Zhongzhen Guan^b ; Zhendong Chen^c ; Chao-Jung Tsao^d ; Shukui Qin^e ; Jun Suk Kim^f ; Tsai-Sheng Yang^g ; Won Young Tak^h ; Hongming Panⁱ ; Shiying Yu^j ; Jianming Xu^k ; Fang Fang^l ; Jessie Zou^l ; Giuseppe Lentini^m ; Dimitris Voliotis^l ; Yoon-Koo Kangⁿ
• 关键词：Hepatocellular carcinoma ; Sorafenib ; Subset analyses
• 刊名：European Journal of Cancer
• 出版年：2012
• 出版时间：July, 2012
• 年：2012
• 卷：48
• 期：10
• 页码：1452-1465
• 全文大小：552 K

文摘

Background

The phase III Sorafenib Asia-Pacific (AP) trial¡ªconducted in China, Taiwan and South Korea - confirmed that sorafenib improves overall survival (OS) and is safe for patients with advanced hepatocellular carcinoma (HCC). We performed a series of exploratory subset analyses to determine whether baseline status affected response to sorafenib.

Methods

In the Sorafenib AP trial, 226 patients with well-preserved liver function (>95 % Child-Pugh A) were randomised 2:1 to sorafenib 400 mg bid or matching placebo. Subanalyses were based on aetiology (hepatitis B virus present/absent); tumour burden (macroscopic vascular invasion and/or extrahepatic spread present/absent); presence or absence of either lung or lymph node metastasis at baseline, Eastern Cooperative Oncology Group performance status (0, 1-2); serum concentrations of alanine aminotransferase/aspartate aminotransferase (normal, mildly elevated, moderately elevated), alpha-fetoprotein (normal/elevated) and total bilirubin (normal/elevated); and whether or not there was a history of hepatectomy or transarterial chemoembolisation/embolisation. Subgroup assessments included OS, time to progression (TTP), disease control rate and safety.

Findings

Sorafenib consistently improved both median OS and median TTP, compared with placebo (range of hazard ratios (HR), 0.32-0.87 and 0.31-0.75, respectively). The most common grade 3/4 adverse events were hand-foot skin reaction, diarrhoea and fatigue, the incidence of which was similar between subgroups.

Interpretation

The efficacy and safety profiles of sorafenib in the subpopulations described were comparable with those in the overall study population. These exploratory analyses suggest that sorafenib is effective for patients from the AP region with advanced HCC, irrespective of baseline status.